XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development [1] $ 31,160 $ 27,201
Acquired in-process research and development [2] 0 825
Selling, general and administrative 14,929 11,045
Total operating expenses 46,089 39,071
Loss from operations (46,089) (39,071)
Other income:    
Other income, net 2,593 3,750
Total other income, net 2,593 3,750
Net loss (43,496) (35,321)
Other comprehensive income (loss)    
Unrealized gain on available-for-sale securities, net of tax 1 157
Comprehensive loss $ (43,495) $ (35,164)
Net loss per share attributable to common stockholders, basic $ (0.38) $ (0.32)
Net loss per share attributable to common stockholders,diluted $ (0.38) $ (0.32)
Weighted-average common shares outstanding, basic 115,618,209 108,785,519
Weighted-average common shares outstanding, diluted 115,618,209 108,785,519
[1] Includes related-party amounts of $1,135 and $2,960 for the three months ended March 31, 2024 and 2023, respectively (see Note 14).
[2] Includes related-party amounts of $0 and $375 for the three months ended March 31, 2024 and 2023, respectively (see Note 14).